TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ELI LILLY & CO Stock
Certificat
DE000SU99231
| Market Closed - Boerse Frankfurt Warrants 03:43:37 2024-05-31 pm EDT | ||
| 44.18 EUR | -0.54% |
|
| Current month | -7.81% | ||
| 1 month | -7.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 44.51 | +0.20% |
| 24-05-30 | 44.42 | -0.65% |
| 24-05-29 | 44.71 | -0.97% |
| 24-05-28 | 45.15 | +1.80% |
| 24-05-27 | 44.35 | -0.96% |
Real-time Boerse Frankfurt Warrants
Last update May 31, 2024 at 03:43 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU9923 |
| ISIN | DE000SU99231 |
| Date issued | 2024-03-05 |
| Strike | 1,293 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 46.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 53.6 € |
|---|---|
| Lowest since issue | 43.52 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Certificates
- Certificat
